Reaction from the field
Manulife’s recent partnership with Guardant Health marks a significant advancement in preventive healthcare across Asia. As the first insurer in the region to offer the Shield Multi-Cancer Detection (MCD) test, Manulife is poised to empower its customers with a vital tool for proactive health management. This initiative is expected to enhance access to early cancer detection, potentially saving lives and improving health outcomes.
The Shield MCD test, which screens for ten of the most common cancers, will be available to eligible Manulife customers starting in April 2026. This timeline reflects a growing commitment to integrating innovative health solutions within insurance offerings, aligning with global trends towards preventive care.
Steve Finch, president and CEO of Manulife Asia, emphasized the importance of this initiative, stating, “By being the first insurer in Asia to offer the Shield MCD test, we’re empowering our customers with a credible and valued service that encourages proactive health management.” This sentiment underscores Manulife’s dedication to enhancing the health and wellbeing of its clients.
The Shield MCD test received Breakthrough Device Designation from the US FDA in June 2025, highlighting its potential impact on cancer detection. This designation not only validates the test’s innovative approach but also positions Manulife at the forefront of health technology in the insurance sector.
In addition to this groundbreaking partnership, Manulife Financial has projected a revenue of CA$55.3 billion and earnings of CA$7.7 billion by 2028. This financial outlook reflects the company’s robust growth strategy and commitment to expanding its services in the Asia-Pacific region.
Moreover, Manulife recently announced a 10.2% increase in its quarterly common dividend to C$0.485, demonstrating its strong financial performance and shareholder value. This increase is indicative of the company’s confidence in its operational strategy and future growth prospects.
As Manulife continues to innovate and expand its offerings, the company is also preparing for the upcoming results report from Manulife US REIT on March 18, 2026. Investors and stakeholders will be closely monitoring these developments to gauge the overall health of the company’s financial portfolio.
While the partnership with Guardant Health is a promising step towards enhancing preventive care, uncertainties remain regarding the full implementation and customer uptake of the Shield MCD test. Details remain unconfirmed as the launch date approaches, and further developments are expected in the coming months.
